Klinikum Bremerhaven-Reinkenheide gGmbH
- Address
- Postbrookstrasse 103, Schiffdorfer Damm, 27574 Bremerhaven, Germany
Klinikum Bremerhaven-Reinkenheide gGmbH - Oncology and Wound Healing Research Center
Klinikum Bremerhaven-Reinkenheide gGmbH is a distinguished clinical research institution specializing in advanced oncology trials and innovative regenerative medicine approaches. The center demonstrates particular expertise in personalized breast cancer therapy through participation in multiple ADAPT (Adjuvant Dynamic marker-Adjusted Personalized Therapy) trials, which utilize dynamic biomarker assessment to optimize treatment selection for individual patients.
- Triple-negative and HER2-positive early breast cancer treatment optimization using novel antibody-drug conjugates and combination immunotherapy approaches
- Hormone receptor-positive breast cancer management comparing endocrine therapy combinations with traditional chemotherapy regimens
- Regenerative medicine applications utilizing allogeneic stem cell therapies for therapy-resistant chronic venous ulcers
The center's oncology research portfolio includes cutting-edge neoadjuvant trials evaluating sacituzumab govitecan, trastuzumab-deruxtecan, and ribociclib combinations, focusing on achieving superior pathologic complete response rates while maintaining excellent long-term survival outcomes. Additionally, the facility conducts innovative wound healing studies investigating stem cell-based therapies for chronic venous ulcers, addressing a significant unmet medical need in patients with therapy-resistant wounds.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Bremerhaven-Reinkenheide gGmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells | 2 | Unknown | 2021-08-18 | 2025-01-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.